Laser Capture Microdissection (LCM) is rapidly emerging as an essential tool for the investigation of mechanisms of carcinogenesis, diagnosis and classification of neoplasms, and the evaluation of innovative therapies. The technology was originally developed by investigators at the National Cancer Institute, and the instrument that was ultimately produced (Arcturus PixCell) is now in use in more than 600 sites worldwide. Because the instrument is expensive and requires special expertise for optimal utility, the development of a Core Facility for use of all UCCRC members is an attractive option. The development of a LCM Core Facility at the University of Chicago has been a common goal and high priority of the UCCRC, the Department of Pathology, and the Dean of the Biologic Sciences Division, all of which have made financial commitments to ensure its success. The PixCell instrument was installed within the Department of Pathology in January, 2001. The facility is under the direction of John Hart, M.D., of the section of Surgical Pathology. Maria Tretiakova, M.D., Ph.D., who has hands on training to use LCM has been recruited as Technical Director. The necessary laboratory protocols have been developed and rigorously tested, and a quality assurance program has been instituted. The facility is open to use by the entire University community, and UCCRC members receive services at a discounted rate. Many investigators who are UCCRC members have already committed to use of the facility.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014599-28
Application #
6599179
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-05-15
Project End
2007-03-31
Budget Start
Budget End
Support Year
28
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977

Showing the most recent 10 out of 668 publications